RJA
NBIX icon

Ross\Johnson & Associates’s Neurocrine Biosciences NBIX Stock Holding History

Ross\Johnson & Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$567 – 303
2025
Q4 		$567 Buy
+4
New +$579 0.01% 142

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ross\Johnson & Associates's NBIX Position: Q1 2026 in Review

Ross\Johnson & Associates sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 4 shares — an estimated $567 sold.

Ross\Johnson & Associates first reported a position in NBIX in Q4 2025 and held it in 1 quarter. The position peaked at $567 in Q4 2025. 699 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Ross\Johnson & Associates reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Ross\Johnson & Associates sold 4 Neurocrine Biosciences shares in Q1 2026, an estimated $567.
  • Ross\Johnson & Associates first reported a position in Neurocrine Biosciences in Q4 2025 and held it in 1 quarter.
  • Ross\Johnson & Associates's Neurocrine Biosciences position peaked at $567 in Q4 2025.
  • 699 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Ross\Johnson & Associates's 13F filing for Q1 2026, filed 8 May 2026.